

FibroScan®

by echosens

The **non-invasive gold standard**
solution for comprehensive
management of liver health



FibroScan[®] Expert 630

The complete non-invasive solution for advanced liver disease management

Powered by LSM by VCTE[™], CAP[™] and SSM by VCTE[™] as part of an overall assessment of the liver

- Expanded clinical capabilities with spleen stiffness measurement
- Enhanced exam efficiency with high-speed processing
- Embedded ultrasound guidance eases both liver and spleen targeting



FibroScan[®] Compact 530

The portable non-invasive solution for efficient liver disease management

Powered by LSM by VCTE[™] and CAP[™]

- Adaptive design and ergonomics for any point-of-care setting: from cart-based to transportable



FibroScan[®] Mini+ 430

The mobile non-invasive solution for liver disease management, ideal for multi-site configuration

Powered by LSM by VCTE[™] and CAP[™]

- Designed for multi-site sharing and near-patient testing
- Winner of the Red Dot Design Award



SSM by VCTE[™] is only available on the FibroScan[®] Expert 630 model

FibroScan[®] Mini+ 430 or FibroScan[®] Mini 430; product name may differ depending on country

FibroScan[®] is powered by **three unique, patented and validated biomarkers** to quickly and easily assess liver health.

Our solutions enable non-invasive diagnosis and monitoring at the point-of-care.

LSM by VCTE[™]

Liver fibrosis assessment

3,800+ publications

The standard for the non-invasive evaluation of liver stiffness.¹ 3,800+ peer-reviewed publications support the use of LSM by VCTE[™]. Relevant in all Chronic Liver Diseases.

CAP[™]

Liver steatosis assessment

1,130+ publications

1,130+ peer-reviewed publications support the use of CAP[™]. Relevant in Steatotic Liver Diseases: MASLD, MASH, MetALD and ALD.

SSM by VCTE[™]

Portal hypertension assessment and variceal surveillance*

134+ publications

134+ peer-reviewed publications support the use of SSM by VCTE[™]. Relevant in the management and risk stratification of patients with advanced chronic liver disease.^{2,3,4}

* SSM is a marker for non-invasive evaluation of spleen stiffness which has been used in a clinical setting to assess portal hypertension and for variceal surveillance.

FibroScan[®] probes

Optimize measurement accuracy on all patient morphologies

S+ Probe

For pediatric population

Designed for being placed into narrow intercostal space

M+ Probe

For patients with standard morphotype

Probe compatible with Guided VCTE[™]

XL+ Probe

For patients with obesity and extreme obesity

Designed to enhance signal penetration through deeper tissues
Probe compatible with Guided VCTE[™]



Related products

Liver Health Management solutions



Advancing Liver Health Management for all

Echosens introduces the Liver Health Management platform, an innovative cloud-based solution that helps clinicians provide accessible longitudinal liver care for their patients. By helping clinicians and their patients take greater control of liver disease, we aspire to improve liver health for everyone. Echosens developed an ecosystem of solutions to support clinical decisions for physicians.

LHM platform is currently available in some countries. Contact us to find out if LHM platform is available in your country or when it will be launched.



Enhancing FibroScan[®] liver disease assessment with biological markers

Fast

Identification of patients with at-risk MASH

Agile 3+

Identification of advanced fibrosis in patients with MASLD

Agile 4

Identification of cirrhosis in patients with MASLD



Your FibroScan[®] companion with Echosens Scores and Interpretation Guide

Available on myfibrosan.com and applications



Real-time secure transfer of exam results to your EHR



NEW

Guided VCTE™

Seamless liver health assessment for all

Intuitive features for faster examinations and simplified scanning⁵

- Two new indicators that allow for quick identification of the optimal measurement location
- AutoScan feature which triggers 10 valid measurements through a single click
- SmartExam features fully included: SmartDepth and Continuous CAP™




Renowned Publication Presence & Endorsement in Clinical Practice Guidelines


4,200+ peer-reviewed publications

180+ international guidelines

More than 4,200 peer-reviewed publications and 180 international guidelines advocate the use of FibroScan® as the reference non-invasive solution for liver fibrosis, cirrhosis, and steatosis assessment **across all etiologies of chronic liver disease (viral hepatitis, MASLD/MASH, alcoholic liver disease)**.^{4,6,7}



Examinations with FibroScan® can inform treatment decisions across the spectrum of disease



The non-invasive gold standard solution for comprehensive management of liver health

Which FibroScan® is right for you?



Capabilities	Guided VCTE™	•	•	•
	SmartExam features fully included	•	•	•
	LSM by VCTE™	•	•	•
	CAP™	•	•	•
Features	SSM by VCTE™	•	•	•
	LHM compatibility	•	•	•
	FibroScan® Gateway compatibility	•	•	•
	myFibroScan® compatibility	•	•	•
	Two probe connectors to easily switch between probes during the examination	•	•	•
	Embedded ultrasound localization system			•
	High-speed processing			•
Ergonomics	Integrated barcode reader			•
	Fully transportable	•	•	
	Battery-powered	•	•	
	Airplane-compatible suitcase	•		
	Option: roll stand		•	
	Weight	11 lbs. / 5 kg	22 lbs. / 10 kg	101 lbs. / 46 kg

Dedicated customer service and support

We will support you with a full range of services: technical support, probe calibrations, maintenance and more.

Interested in FibroScan® for your practice?

Contact us on echosens.com

LSM: Liver Stiffness Measurement / SSM: Spleen Stiffness Measurement / CAP™: Controlled Attenuation Parameter / VCTE™: Vibration-Controlled Transient Elastography / MASLD: Metabolic dysfunction-associated steatotic liver disease (formerly known as NAFLD) / MASH: Metabolic dysfunction-associated steatohepatitis (formerly known as NASH) / MetALD: MASLD and increase alcohol intake / ALD: Alcohol-associated liver disease / MASLD-MASH formerly known as NAFLD-NASH / LHM: Liver Health Management

References

1. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Hígado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006. 2. Stefanescu H, et al. A novel spleen-dedicated stiffness measurement by FibroScanR improves the screening of high-risk oesophageal varices. Liver Int. 2020;40(1):175-185. doi:10.1111/liv.14228. 3. Dajti, Elton et al. "A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease." The American journal of gastroenterology vol. 117,11 (2022): 1825-1833. doi:10.14309/ajg.0000000000001887. 4. Baveno VII - R. de Franchis et al. Renewing consensus in portal hypertension. Journal of hepatology vol. 76,4 (2022): 959-974. doi:10.1016/j.jhep.2021.12.022. 5. Based on internal data. E431R020.1. 6. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu et al. "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update." Journal of hepatology vol. 75,3 (2021): 659-689. 7. Kanwal, Fasiha et al. "Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease." Gastroenterology vol. 161,5 (2021): 1657-1669.

Products in the FibroScan® range are class IIa medical devices according to Rule 10 of ANNEX VIII of Regulation EU 2017/745 (CE 0459) and are manufactured by Echosens™. FibroScan® devices are intended to provide: Liver stiffness measurements at a shear wave frequency of 50 Hz, liver ultrasound attenuation measurements (CAP: Controlled Attenuation Parameter) at 3.5 MHz and spleen stiffness measurements at a shear wave frequency of 100 Hz (FibroScan® 630 Expert only). These non-invasive devices are intended to aid clinical management, diagnosis, and monitoring of patients with confirmed or suspected chronic liver disease, as part of an overall assessment of the liver. FibroScan® devices may aid the healthcare professionals in the assessment of liver fibrosis, steatosis, and in determining the likelihood of cirrhosis, and its complications (FibroScan® 630 Expert only). They are used, in conjunction with other clinical and laboratory data, during liver assessment in patients with confirmed or suspected chronic liver disease. Examinations with FibroScan® devices shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. Fast is an in vitro diagnostic medical device according to directive 98/79/EC. Agile 3+ and Agile 4 are class I medical devices according to Directive 93/42/EEC. Fast, Agile 3+ and Agile 4 are manufactured by Echosens. Fast calculator is a tool for clinicians, computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of NAFLD as being at risk for active fibrotic NASH (NASH+NAs≥4+F≥2). It was developed based on a prospective multicenter cohort and published in peer-reviewed literature. Agile 3+ calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of NAFLD as having advanced fibrosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Agile 4 calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status and gender, to aid in the identification of patients with suspicion of NAFLD as having cirrhosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Fast™, Agile 3+ and Agile 4 are presented as educational services intended for licensed healthcare professionals. While these scores are about specific medical and health issues, they are not a substitute for or a replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. Users are expressly recommended to carefully read the instructions given in the user manual. User manual is available on the Score interface or Echosens website. To access, please make sure to be connected to the internet. This marketing material is not intended for US audience. © 2024 Echosens - Echosens™ and FibroScan® are trademarks owned by Echosens SA. All rights reserved. Brochure CAPEX Range - v3 ROW - 09/2024.